$21.21-0.10 (-0.47%)
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
Tectonic Therapeutic, Inc. in the Healthcare sector is trading at $21.21 with a market capitalization of $736M. Wall Street consensus targets $71.00 (9 analysts), implying a +234.7% move over the next 12 months. The stock is currently 46% below its 52-week high of $39.53, remaining 24.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$24.22Mβ | -$27.30Mβ | -$21.52Mβ | -$21.89Mβ | -$22.33M |
| Net Income | -$22.29Mβ | -$25.24Mβ | -$19.23Mβ | -$19.04Mβ | -$19.98M |
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the ...